I am hoping the $5Million from Hologic is in the current quarterly and they would have to comment on the uptake of Febridx otherwise this is going to flouder around for another 4 months. Net30/60 day arrangement etc would have an effect on receipts, however they could still provide guidance on how much sales they have made to date and when this is expected, no?
Point i am making is that if sales from Viradx/Febridx are =$300,000 USD, then annually we will be making more than previous years. Anything greater and it means uptake in the US market is evident. Once CLIA waiver comes into play, you would then expect that to grow even more.
Add in further licencing deals which could be on the cards etc. If the same IP deals are signed, then thats just a bonus.
The issue I see with the Hologic announcement is that it didnt indicate to the market about annuities for the product service. It just reads as a one off payment.
Simple fact is, the ASX share prices improve on two metrics: How much lithium is in the drill tests and for everyone else, ongoing revenue.
Add to My Watchlist
What is My Watchlist?
